Siltuximab vs placebo or usual care
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.97 [0.79, 1.18]1 study · 148 participantsVery low